These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 37166279)

  • 1. High-grade serous ovarian carcinoma organoids as models of chromosomal instability.
    Vias M; Morrill Gavarró L; Sauer CM; Sanders DA; Piskorz AM; Couturier DL; Ballereau S; Hernando B; Schneider MP; Hall J; Correia-Martins F; Markowetz F; Macintyre G; Brenton JD
    Elife; 2023 May; 12():. PubMed ID: 37166279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rescue of p53 functions by in vitro-transcribed mRNA impedes the growth of high-grade serous ovarian cancer.
    Raab M; Kostova I; Peña-Llopis S; Fietz D; Kressin M; Aberoumandi SM; Ullrich E; Becker S; Sanhaji M; Strebhardt K
    Cancer Commun (Lond); 2024 Jan; 44(1):101-126. PubMed ID: 38140698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of tandem duplicator phenotype in tumour evolution in high-grade serous ovarian cancer.
    Ng CK; Cooke SL; Howe K; Newman S; Xian J; Temple J; Batty EM; Pole JC; Langdon SP; Edwards PA; Brenton JD
    J Pathol; 2012 Apr; 226(5):703-12. PubMed ID: 22183581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromosome instability is prevalent and dynamic in high-grade serous ovarian cancer patient samples.
    Morden CR; Farrell AC; Sliwowski M; Lichtensztejn Z; Altman AD; Nachtigal MW; McManus KJ
    Gynecol Oncol; 2021 Jun; 161(3):769-778. PubMed ID: 33714608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human Fallopian Tube-Derived Organoids with TP53 and RAD51D Mutations Recapitulate an Early Stage High-Grade Serous Ovarian Cancer Phenotype In Vitro.
    Dai Y; Xu J; Gong X; Wei J; Gao Y; Chai R; Lu C; Zhao B; Kang Y
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids.
    Cesari E; Ciucci A; Pieraccioli M; Caggiano C; Nero C; Bonvissuto D; Sillano F; Buttarelli M; Piermattei A; Loverro M; Camarda F; Greco V; De Bonis M; Minucci A; Gallo D; Urbani A; Vizzielli G; Scambia G; Sette C
    J Exp Clin Cancer Res; 2023 May; 42(1):126. PubMed ID: 37202753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ovarian Cancer Patient-Derived Organoids Used as a Model for Replicating Genetic Characteristics and Testing Drug Responsiveness: A Preliminary Study.
    Chang YH; Wu KC; Wang KH; Ding DC
    Cell Transplant; 2024; 33():9636897241281869. PubMed ID: 39323050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Classification of High-Grade Serous Ovarian Carcinoma by Epithelial-to-Mesenchymal Transition Signature and Homologous Recombination Repair Genes.
    Sohn MH; Kim SI; Shin JY; Kim HS; Chung HH; Kim JW; Lee M; Seo JS
    Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine.
    Nero C; Vizzielli G; Lorusso D; Cesari E; Daniele G; Loverro M; Scambia G; Sette C
    J Exp Clin Cancer Res; 2021 Mar; 40(1):116. PubMed ID: 33789687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next-generation sequencing shows the genomic features of ovarian clear cell cancer and compares the genetic architectures of high-grade serous ovarian cancer and clear cell carcinoma in ovarian and endometrial tissues.
    Gan M; Tai Z; Yu Y; Zhang C; Xu J
    PeerJ; 2023; 11():e14653. PubMed ID: 36721777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Copy number signatures and mutational processes in ovarian carcinoma.
    Macintyre G; Goranova TE; De Silva D; Ennis D; Piskorz AM; Eldridge M; Sie D; Lewsley LA; Hanif A; Wilson C; Dowson S; Glasspool RM; Lockley M; Brockbank E; Montes A; Walther A; Sundar S; Edmondson R; Hall GD; Clamp A; Gourley C; Hall M; Fotopoulou C; Gabra H; Paul J; Supernat A; Millan D; Hoyle A; Bryson G; Nourse C; Mincarelli L; Sanchez LN; Ylstra B; Jimenez-Linan M; Moore L; Hofmann O; Markowetz F; McNeish IA; Brenton JD
    Nat Genet; 2018 Sep; 50(9):1262-1270. PubMed ID: 30104763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploiting a living biobank to delineate mechanisms underlying disease-specific chromosome instability.
    Nelson L; Barnes BM; Tighe A; Littler S; Coulson-Gilmer C; Golder A; Desai S; Morgan RD; McGrail JC; Taylor SS
    Chromosome Res; 2023 Aug; 31(3):21. PubMed ID: 37592171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dualistic classification of high grade serous ovarian carcinoma has its root in spatial heterogeneity.
    Sun T; Zhang Z; Tian L; Zheng Y; Wu L; Guo Y; Li X; Li Y; Shen H; Lai Y; Liu J; Cui H; He S; Ren Y; Yang G
    J Adv Res; 2023 Jun; 48():213-225. PubMed ID: 36038111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation and Culturing of High-Grade Serous Ovarian Cancer Patient-Derived Organoids.
    Graham O; Rodriguez J; van Biljon L; Fashemi B; Graham E; Fuh K; Khabele D; Mullen M
    J Vis Exp; 2023 Jan; (191):. PubMed ID: 36688549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatic Mutational Profile of High-Grade Serous Ovarian Carcinoma and Triple-Negative Breast Carcinoma in Young and Elderly Patients: Similarities and Divergences.
    Serio PAMP; de Lima Pereira GF; Katayama MLH; Roela RA; Maistro S; Folgueira MAAK
    Cells; 2021 Dec; 10(12):. PubMed ID: 34944094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment and Characterization of the Novel High-Grade Serous Ovarian Cancer Cell Line OVPA8.
    Tudrej P; Olbryt M; Zembala-Nożyńska E; Kujawa KA; Cortez AJ; Fiszer-Kierzkowska A; Pigłowski W; Nikiel B; Głowala-Kosińska M; Bartkowska-Chrobok A; Smagur A; Fidyk W; Lisowska KM
    Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30018258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic Characterization of High-Grade Serous Ovarian Cancer: Dissecting Its Molecular Heterogeneity as a Road Towards Effective Therapeutic Strategies.
    Mittempergher L
    Curr Oncol Rep; 2016 Jul; 18(7):44. PubMed ID: 27241520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clonal somatic copy number altered driver events inform drug sensitivity in high-grade serous ovarian cancer.
    Martins FC; Couturier DL; de Santiago I; Sauer CM; Vias M; Angelova M; Sanders D; Piskorz A; Hall J; Hosking K; Amirthanayagam A; Cosulich S; Carnevalli L; Davies B; Watkins TBK; Funingana IG; Bolton H; Haldar K; Latimer J; Baldwin P; Crawford R; Eldridge M; Basu B; Jimenez-Linan M; Mcpherson AW; McGranahan N; Litchfield K; Shah SP; McNeish I; Caldas C; Evan G; Swanton C; Brenton JD
    Nat Commun; 2022 Oct; 13(1):6360. PubMed ID: 36289203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiomic Analysis of Subtype Evolution and Heterogeneity in High-Grade Serous Ovarian Carcinoma.
    Geistlinger L; Oh S; Ramos M; Schiffer L; LaRue RS; Henzler CM; Munro SA; Daughters C; Nelson AC; Winterhoff BJ; Chang Z; Talukdar S; Shetty M; Mullany SA; Morgan M; Parmigiani G; Birrer MJ; Qin LX; Riester M; Starr TK; Waldron L
    Cancer Res; 2020 Oct; 80(20):4335-4345. PubMed ID: 32747365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.
    Alkema NG; Wisman GB; van der Zee AG; van Vugt MA; de Jong S
    Drug Resist Updat; 2016 Jan; 24():55-69. PubMed ID: 26830315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.